Prof David Bowtell
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
528 Scholarly works
61 Projects
HIGHLIGHTS
2026
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2024
Journal article
BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance
DOI: 10.1186/s12943-024-02048-12022
Research grants (ARC, NHMRC, MRFF)
Driving Improvements in Ovarian Cancer Survival Through Molecular and Clinical Studies
2020
Research grants (ARC, NHMRC, MRFF)
Super-Next: Complete Genome Profiling for Cancer of Unknown Primary
2018
Journal article
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma
DOI: 10.1038/s41467-018-05564-z2017
Journal article
Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma
DOI: 10.1158/2159-8290.CD-17-04192016
Journal article
Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patients
DOI: 10.1158/1078-0432.CCR-15-1931
RECENT SCHOLARLY WORKS
2026
Journal article
Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma
DOI: 10.1038/s41467-026-71134-32026
Journal article
FAPI-CUP: A prospective cohort study of patients with cancer of unknown primary (CUP) to evaluate a novel radiotracer, fibroblast activated protein (FAPI), targeting cancer-associated fibroblasts for primary site detection.
DOI: 10.1200/jco.2026.44.16_suppl.30722026
Journal article
IGNITE-Cerala: A phase II signal-seeking trial of ceralasertib targeting recurrent high-grade serous ovarian cancer with cyclin E1 overexpression with and without gene amplification.
DOI: 10.1200/jco.2026.44.16_suppl.55872026
Journal article
Rethinking ovarian cancer III: the past decade and future directions
DOI: 10.1038/s41568-026-00916-02026
Journal article
Real-world comparative outcomes of neoadjuvant chemotherapy with interval cytoreductive surgery versus primary cytoreductive surgery in epithelial ovarian cancer: insights from the australian ovarian cancer study (AOCS)
DOI: 10.1016/j.ijgc.2025.1030762025
Journal article
762MO Clinical whole genome and transcriptome sequencing for cancer of unknown primary: An Australian prospective observational study
DOI: 10.1016/j.annonc.2025.10.11772025
Journal article
Overcoming intra-tumoral heterogeneity for biomarker discovery in the high-grade serous ovarian cancer proteome
DOI: 10.1038/s41698-025-00911-y2025
Other
Supplementary Figures S1-S4 from The Prognostic Effect of Immune Cell Infiltration Depends on Molecular Subtype in Endometrioid Ovarian Carcinomas
DOI: 10.1158/1078-0432.30708505